Table 1. Randomized controlled study of TACE combined with targeted therapy.

Experimental arms	Stage	Endpoints and outcomes	Ref.
TACE, transcatheter arterial chemoembolization; DEB-TACE, drug-eluting Beads TACE; RT, external beam radiotherapy; BCLC, Barcelona Clinic Liver Cancer; uHCC, unresectable hepatocellular carcinoma; MVI, microvascular invasion; PVTT, portal vein tumor thrombus; TTP, time-to-progression; OS, overall survival; PFS, progression-free survival; ORR, objective response rate; HR, hazard ratio; 95% CI, 95% confidence interval.
DEB-TACE+sorafenib vs. DEB-TACE	BCLC-B/C, uHCC	TTP: 169 vs. 166 d (HR=0.797, P=0.072)	(151)
DEB-TACE+sorafenib vs. DEB-TACE	BCLC-B/C, uHCC	PFS: 238.0 d (95% CI, 221.0−281.0) vs. 235.0 d (95% CI, 209.0−322.0)	(152)
TACE+RT+sorafenib vs. sorafenib	HCC with MVI	PFS: 86.7% vs. 34.3% (P<0.001)	(153)
TARE+sorafenib vs. sorafenib	uHCC	OS: 12.1  vs. 11.4 months (HR=1.01; 95% CI, 0.81−1.25; P=0.9529)	(154)
TACE+sorafenib vs. sorafenib	uHCC	PFS: 25.2 vs. 13.5 months (P=0.006)	(155)
TACE+lenvatinib vs. TACE+sorafenib	HCC with PVTT	TTP: 4.7 vs. 3.1 months (HR=0.55; 95% CI, 0.32−0.95; P=0.029)	(156)
TACE+lenvatinib vs. lenvatinib	advanced HCC	OS: 17.8 vs. 11.5 months (HR=0.45; P<0.001)	(21)
TACE+bevacizumab vs. TACE	uHCC	PFS: At 16 weeks, 0.79 vs. 0.19 (P=0.021)	(157)
TACE+sorafenib vs. TACE	BCLC-B, HCC	TTP: 9.2 vs. 4.9 months (HR=2.5; 95% CI, 1.66−7.56; P<0.001)	(158)
TACE+brivanib vs. TACE	uHCC	OS: 26.4 vs. 26.1 months (HR=0.9; 95% CI, 0.66−1.23; P=0.528)	(159)
TACE+bevacizumab vs. TACE	BCLC-A/B, uHCC	OS: 5.3 vs. 13.7 months (HR=1.7; 95% CI, 0.8−3.6; P=0.195)	(160)
TACE+apatinib vs. TACE	uHCC	mPFS: 12.5 vs. 6 months (P<0.05)	(161)
TACE+orantinib vs. TACE	uHCC	OS: 31.1 vs. 32.3 months (HR=1.09; 95% CI, 0.878−1.352; P=0.435)	(162)
Yttrium-90 radioembolization + sorafenib vs. sorafenib	Not eligible for TACE	OS: 14.0 vs. 11.1 months (HR=0.86; P=0.2515)	(154)